Mark Sulkowski, MD






Site Investigator

  • Vice-chair, Hepatitis TSG
  • Vice-Chair, Steering Committee of Hepatitis TSG (Dec 2014)
  • Member, HBV Cure Working Group of the HEP TSG (Mar 2015)
  • Co-Vice-Chair, NASH Focus Group of the ITSG/HEPTSG (April 2016)
  • Chair ACTG 5329
  • Co-chair ACTG 5334s
  • Investigator, ACTG 5335s


Leadership Committees

Clinical Trials

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

A5354/EARLIER: Effect of Antiretroviral Treatment Initiated...

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More